๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy

โœ Scribed by Jeanne M. Manson; Cecile Freyssinges; Marie B. Ducrocq; Wendy P. Stephenson

Book ID
114274060
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
798 KB
Volume
10
Category
Article
ISSN
0890-6238

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pregnancy outcomes after maternal exposu
Pregnancy outcomes after maternal exposure to simvastatin and lovastatin
โœ Pia S. Pollack; Kristine E. Shields; Diane M. Burnett; Mary Jean Osborne; Michae ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 167 KB ๐Ÿ‘ 1 views

## BACKGROUND: Our objective was to determine the frequency of adverse outcomes after maternal exposure to simvastatin and/or lovastatin during pregnancy in postmarketing experience. METHODS: We reviewed the Merck & Co., Inc. (West Point, PA) pharmacovigilance database for reports of exposure to s

Postmarketing surveillance for drug safe
Postmarketing surveillance for drug safety in pregnancy: The Organization of Teratology Information Services Project
โœ Robert J. Felix; Kenneth Lyons Jones; Kathleen A. Johnson; Carolyn A. McCloskey; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB

## Abstract ## BACKGROUND Although medications are frequently used during pregnancy, premarketing studies exclude pregnant women, with the result that maternal and fetal risks of medications are largely unknown prior to marketing. ## METHODS To demonstrate the feasibility of using Teratology Inf